Why the study?
As anti-obesity treatments advance, the impact of body mass index on clinical outcomes in heart failure with reduced ejection fraction requires clearer understanding.
Does a BMI >27 kg/m² increase the risk of mortality and heart failure hospitalization in clinically stable, medically optimized HFrEF patients?
Cohort (n=1,017)
Yes
Does a BMI >27 kg/m² increase the risk of mortality and heart failure hospitalization in clinically stable, medically optimized HFrEF patients?
Effect estimate: HR 1.18 (95% CI 0.94-1.48)
In patients with HFrEF, particularly those with ischemic cardiomyopathy, a BMI >27 kg/m² is associated with worse cardiovascular outcomes, challenging the obesity-survival paradox.
Background Obesity is common in heart failure with reduced ejection fraction (HFrEF). As anti-obesity treatments advance, understanding how body mass index (BMI) affects outcomes in HFrEF is increasingly important. Objective To examine whether a BMI >27 kg/m² is linked to higher risks of all-cause mortality, cardiovascular death, and heart failure (HF) hospitalization in HFrEF patients. Methods This study included 1,017 clinically stable, medically optimized HFrEF patients from the NorthStar study (2005–2009), followed through 2023 using Danish registries. Outcomes were assessed with Cox models adjusted for prognostic factors. The primary endpoint was all-cause mortality; secondary endpoints included cardiovascular death, HF hospitalization, and a composite of mortality or hospitalization. Subgroup analyses compared BMI categories (<24, 24–27, >27 kg/m²). Results Patients with BMI >27 had more diabetes (27.8% vs. 17.7%) and lower NT-proBNP (median 776 vs. 1,163 pg/mL) than those with BMI 24–27, with similar HF etiology. Over a median 8.8 years, 821 patients (80.7%) died, including 444 cardiovascular deaths, and 740 (72.8%) were hospitalized for HF. A BMI of 35 vs. 27 was associated with non-significant increased all-cause mortality (HR 1.18, 95% CI 0.94–1.48) but significantly higher cardiovascular mortality (HR 1.42, 95% CI 1.05–1.92), HF hospitalization (HR 1.33, 95% CI 1.05–1.67), and composite outcome (HR 1.30, 95% CI 1.06–1.60). Subgroup analysis showed higher mortality with BMI >27 vs. 24–27 in ischemic cardiomyopathy (HR 1.31, 95% CI 1.05–1.64), but not in non-ischemic (HR 0.86, 95% CI 0.66–1.12), interaction p=0.015. Conclusion Among HFrEF patients—especially those with ischemic cardiomyopathy—BMI >27 is associated with worse outcomes, challenging the “obesity-survival paradox” and highlighting the importance of effective weight management.
No takes yet. Share an insight, caveat, or question.
Malmborg et al. (2025) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=1,017). BMI 35 kg/m² vs. BMI 27 kg/m² was evaluated on All-cause mortality (HR 1.18, 95% CI 0.94-1.48).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: